Over 39 million Americans live with migraines, yet a large share of them cycle through medications that either stop working, cause rebound headaches, or were never effective to begin with. If that description fits your experience, the failure is not a character flaw or a gap in effort — it reflects the biology of a condition that conventional pharmacology was not designed to address at its source. At Scottsdale Ketamine Clinic, we work with chronic migraine patients who have exhausted the standard options and are looking for a different mechanism of treatment.
What Makes Chronic Migraine So Resistant to Treatment
A migraine is not simply a bad headache. At the neurological level, a migraine involves a cascade of electrical and chemical events in the brain that triggers intense pain, light and sound sensitivity, nausea, and in some cases visual disturbances called auras. The process begins with cortical spreading depression — a wave of abnormal electrical activity that moves across the brain’s surface — and is followed by the activation of the trigeminal nerve, which sends pain signals through the head and face.
Conventional migraine treatments work primarily at one step in this cascade. Triptans, for example, constrict blood vessels and block pain signals at serotonin receptors. CGRP inhibitors target a specific protein involved in transmitting migraine pain. These drugs help many patients significantly. But for patients with chronic migraine — defined as fifteen or more headache days per month — the nervous system has often undergone a process called central sensitization, where the brain’s pain-processing network becomes hypersensitized to stimuli. At that point, targeting a single receptor or protein may not be sufficient to interrupt the abnormal signaling (National Center for Biotechnology Information).
This is where IV ketamine therapy offers a different approach.
The Glutamate System and Why It Matters for Migraines
Most people are familiar with serotonin and dopamine. Far fewer have heard of glutamate — and yet glutamate is the brain’s primary excitatory neurotransmitter, responsible for most of the brain’s fast signaling. In chronic migraine, glutamate plays a central and problematic role. Elevated glutamate levels and overactive NMDA receptors — the glutamate receptors responsible for amplifying pain signals — are a consistent finding in migraine research. This NMDA overactivity is closely tied to the central sensitization that makes chronic migraine so difficult to treat with conventional medications (National Center for Biotechnology Information).
Ketamine’s primary mechanism of action is NMDA receptor blockade. It works by temporarily occupying and blocking these overactive receptors, interrupting the pain amplification cycle at a point that other migraine medications simply do not reach (National Center for Biotechnology Information). By dampening NMDA activity, IV ketamine can reduce the hypersensitized state of the nervous system that allows migraines to recur with such frequency and severity. The effect is not just pain suppression during the infusion — it is a recalibration of the abnormal neural signaling patterns that sustain chronic migraine.
What Happens During an Infusion
When you come to our clinic in Scottsdale or our Phoenix location in Ahwatukee, your infusion takes place in a private, comfortable treatment room under continuous clinical supervision. Each session lasts approximately 45 to 60 minutes. You will be monitored throughout by our licensed medical team, which includes Jenice Hughes, CRNA, our board-certified nurse anesthetist with more than four decades of clinical experience in anesthesia and pain management.
During the infusion, you may notice a sense of relaxation, mild alterations in perception, or a feeling of mild detachment. These effects are temporary and resolve shortly after the session ends. You will need to arrange transportation home — driving is not permitted on infusion days. Most patients do not find the experience uncomfortable; the most commonly reported side effects are mild nausea and dizziness, which are brief and manageable in a clinical setting (National Institutes of Health).
Because ketamine works through a different neurological pathway than your prior migraine medications, it does not interact with those treatments in the way a second medication added to the same class might. Whether you are currently on preventive migraine therapy or have discontinued it, we conduct a full clinical intake and evaluation before beginning any treatment to ensure the protocol fits your individual history.
How Many Sessions and What to Expect
For chronic migraine treatment, we build a personalized treatment plan based on your history and how your nervous system responds. Most patients begin with a series of infusions over a defined period, and our team assesses your response as you progress. Some patients experience meaningful relief early in the series; others see improvement build across multiple sessions. Results vary by individual, and we do not make uniform predictions about timing or outcomes.
Maintenance infusions — spaced weeks or months apart — are available for patients who benefit from the initial series and want to sustain those results. The frequency of maintenance sessions depends on how long the effects persist for each individual and the goals you set in collaboration with our clinical team.
It is also worth being direct about cost. IV ketamine infusions are considered off-label treatments for migraine and are not typically covered by insurance. We provide documentation for patients who wish to seek out-of-network reimbursement from their insurer. Our team will walk you through the financial details before you commit to any treatment.
Why Standard Failures Do Not Predict Ketamine Outcomes
One of the most common questions we hear from patients with long treatment histories is whether their previous failures mean ketamine will also fail. The short answer is no — and here is why.
Every medication you have tried for migraines has operated within the same general framework: targeting serotonin receptors, CGRP proteins, or adrenergic pathways. These are all downstream mechanisms in the migraine cascade. Ketamine operates further upstream, at the NMDA receptor level, and its effects on neuroplasticity — the brain’s capacity to form new neural connections and reorganize existing ones — are not replicated by any conventional migraine drug (National Center for Biotechnology Information). A treatment history full of failed conventional medications tells us that those downstream mechanisms were not sufficient for your neurobiology. It does not say anything about what happens when you address the NMDA pathway directly.
This does not mean ketamine is appropriate for every chronic migraine patient. Not everyone is a candidate, and our intake and evaluation process exists for exactly that reason. But the distinction between mechanism classes matters, and it is the reason many patients who had exhausted their options found a different response with IV infusion therapy. If you want to understand how we approach candidacy for migraine patients specifically, our ketamine FAQs address the most common eligibility and safety questions.
Addressing the Hesitation
We understand that patients who have been through years of failed treatments approach anything new with a mix of guarded hope and practical skepticism. That is rational, and we do not ask patients to set it aside. What we ask is that you discuss your options with a qualified provider who can evaluate your specific history — not a general description of chronic migraine, but your history, your prior treatments, and your current neurological picture.
If you have concerns about the infusion experience, about what the dissociative effects feel like, or about the commitment of a multi-session protocol, those are conversations we have at consultation. We do not expect you to arrive already convinced. We expect you to arrive with questions, and we work through them.
Frequently Asked Questions
Is IV ketamine the same thing as the ketamine used recreationally? Ketamine has been used in medical settings as an anesthetic for more than fifty years. At therapeutic doses administered intravenously in a clinical environment, it functions very differently than recreational use. The dose, route of administration, clinical setting, and monitoring are all distinct. That said, ketamine is not appropriate for patients with certain psychiatric or medical histories, which is why a thorough screening is required before treatment begins.
How is ketamine different from the migraine medications I’ve already tried? Most migraine medications target serotonin receptors (triptans), CGRP proteins, or adrenergic pathways. Ketamine works on the NMDA receptor in the glutamate system — a fundamentally different mechanism that other migraine treatments do not address. For patients whose chronic migraines involve central sensitization, this distinction can be clinically significant.
Will I feel the effects right away after a session? Some patients notice improvement during or shortly after their first infusion. Others see changes build across multiple sessions. We do not guarantee a specific timeline because individual responses vary. Our team will assess your progress throughout the treatment series and adjust the plan accordingly.
Do I need to stop my current migraine medications to start ketamine therapy? Not necessarily. Whether you continue current medications alongside ketamine infusions depends on your specific history and treatment goals. We review all current medications during your intake evaluation and make individualized recommendations — we do not apply a blanket protocol. Discuss this with your provider as part of your consultation.
What does the consultation involve? Your initial consultation is a conversation with a member of our clinical team. We review your medical and migraine history, the treatments you have tried and how you responded, and your current symptoms and goals. From there, we determine whether IV ketamine is an appropriate option and outline what a treatment plan would look like for you. Consultations are free.
Key Takeaways
- Chronic migraine involves central sensitization — a hypersensitized pain-processing state that conventional medications often cannot fully address because they target downstream mechanisms.
- IV ketamine works on NMDA receptors in the glutamate system, upstream from the pathways targeted by triptans and CGRP inhibitors, giving it a distinct mechanism relevant to central sensitization.
- A history of failed conventional migraine treatments does not predict ketamine outcomes, because prior medications operated through entirely different neurological pathways.
- Treatment at Scottsdale Ketamine Clinic is personalized: protocols are built around your history, and maintenance infusions are available for patients who benefit from the initial series.
- IV ketamine for migraines is currently off-label and not typically covered by insurance; our team provides documentation to support out-of-network reimbursement requests.
Chronic migraine is not a condition that rewards patience with the same treatments on repeat. If you have worked through the standard options without adequate relief, a conversation about IV ketamine infusion therapy is a reasonable next step — not a last resort, but a different mechanism that your prior treatments never addressed. Call our Scottsdale clinic at 480-613-3226 or our Phoenix location at 480-590-6154 to schedule a free consultation. We will give you a straight answer about whether this is appropriate for your situation, and we will not ask you to arrive with any assumptions except your own history.
References
National Center for Biotechnology Information. Ketamine for Chronic Pain. https://www.ncbi.nlm.nih.gov/books/NBK539824/
National Center for Biotechnology Information. Migraines. https://pmc.ncbi.nlm.nih.gov/articles/PMC9506374/
National Center for Biotechnology Information. NMDA Receptor / Glutamate System (Ketamine Mechanism of Action). https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
National Institutes of Health. Side Effects Mild and Brief from Single Antidepressant Dose of Intravenous Ketamine. https://www.nih.gov/news-events/news-releases/side-effects-mild-brief-single-antidepressant-dose-intravenous-ketamine
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. IV ketamine infusion therapy for migraines or chronic pain should only be pursued under the supervision of a licensed medical provider familiar with your full medical history. Individual results vary. Not all patients are candidates for ketamine therapy. If you are experiencing a medical emergency, please call 911 or go to your nearest emergency room.





